Table 1 Patient characteristics and ICU treatment of 81 patients admitted to intensive care due to severe COVID-19 divided by findings of SARS-COV-2 in urine or not. Values are represented as median (IQR) or n (%). Data for “SAPS3” and “Days between onset of symptoms and sampling” were missing for one and 4 patients, respectively, in the group negative for SARS-COV-2 in urine. The p value originates from the Mann-Whitney U test for continuous parameters and the chi-square test for categorical parameters. Values are represented as median (IQR) or n (%). p < 0.05 is considered significant. AKI acute kidney injury
SARS-COV-2 urine negative | SARS-COV-2 urine positive | p | |
|---|---|---|---|
(n = 75) | (n = 6) | ||
Gender, female, n (%) | 17 (23) | 2 (33) | 0.57 |
Age, years | 61 (53–70) | 58 (39–69) | 0.59 |
Days between onset of symptoms and sample | 15 (12–16), n = 71 | 14 (12–16) | 0.68 |
Days between ICU admission and sample | 4 (3–4) | 4 (4–5) | 0.33 |
SAPS3 on admission | 53 (47–57), n = 74 | 57 (44–60) | 0.70 |
ICU-free days | 14 (0–19) | 22 (5–22) | 0.26 |
Ventilator-free days | 20 (0–28) | 27 (6–28) | 0.50 |
Renal replacement therapy-free days | 28 (0–28) | 28 (7–28) | 0.95 |
ICU mortality, n (%) | 13 (17) | 2 (33) | 0.37 |
30-day mortality, n (%) | 14 (19) | 2 (33) | 0.41 |
Acute kidney injury, n (%) | 46 (61) | 5 (83) | 0.28 |
Stage I | 23 (31) | 4 (67) | 0.07 |
Stage II | 9 (12) | 0 (0) | 0.36 |
Stage III | 14 (19) | 1 (17) | 0.90 |
Days between onset of AKI and sample | 2 (− 1–4), n = 46 | 6 (5–8), n = 5 | 0.01 |
Days between peak P-creatinine and sample | − 2 (− 7–3), n = 46 | 5 (4–5), n = 5 | 0.03 |